JP2012525376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525376A5 JP2012525376A5 JP2012507877A JP2012507877A JP2012525376A5 JP 2012525376 A5 JP2012525376 A5 JP 2012525376A5 JP 2012507877 A JP2012507877 A JP 2012507877A JP 2012507877 A JP2012507877 A JP 2012507877A JP 2012525376 A5 JP2012525376 A5 JP 2012525376A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- colostrum
- subject
- immunoglobulin preparation
- derived immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17292209P | 2009-04-27 | 2009-04-27 | |
| US61/172,922 | 2009-04-27 | ||
| PCT/IL2010/000339 WO2010125565A2 (en) | 2009-04-27 | 2010-04-27 | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525376A JP2012525376A (ja) | 2012-10-22 |
| JP2012525376A5 true JP2012525376A5 (enExample) | 2013-05-30 |
| JP5740390B2 JP5740390B2 (ja) | 2015-06-24 |
Family
ID=42357536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507877A Expired - Fee Related JP5740390B2 (ja) | 2009-04-27 | 2010-04-27 | 病的障害の治療および／または予防において使用するための抗ｌｐｓ強化免疫グロブリン製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10117930B2 (enExample) |
| EP (2) | EP3461840A1 (enExample) |
| JP (1) | JP5740390B2 (enExample) |
| KR (1) | KR101785120B1 (enExample) |
| AU (1) | AU2010243205B2 (enExample) |
| BR (1) | BRPI1014774A2 (enExample) |
| CA (2) | CA3017477A1 (enExample) |
| DK (1) | DK2424890T3 (enExample) |
| EA (1) | EA024697B1 (enExample) |
| ES (1) | ES2684696T3 (enExample) |
| IL (1) | IL215924B (enExample) |
| MX (1) | MX2011011376A (enExample) |
| SG (1) | SG175142A1 (enExample) |
| WO (1) | WO2010125565A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011290478B2 (en) * | 2010-08-17 | 2014-11-13 | Hadasit Medical Research Services & Development Limited | Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| TW201304786A (zh) * | 2010-10-04 | 2013-02-01 | Immuron Ltd | 使用抗ｌｐｓ配體治療及預防發炎疾病的方法及組合物 |
| PH12013501040A1 (en) | 2010-11-23 | 2022-10-24 | Pantheryx Inc | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| DE102011006781A1 (de) * | 2011-04-05 | 2012-10-11 | Mat-Malta Advanced Technologies Limited | Antikörperprodukt, umfassend n spezifische Antikörper |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| WO2012171077A1 (en) * | 2011-06-17 | 2012-12-20 | Immuron Limited | Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage |
| US8926980B2 (en) * | 2011-07-11 | 2015-01-06 | Camas Incorporated | Compositions against bacterial toxins |
| AU2013204801B2 (en) | 2012-05-23 | 2014-11-06 | Omniblend Innovation Pty Ltd | Composition and method for management of diabetes or pre-diabetes |
| HRP20190030T1 (hr) * | 2012-06-21 | 2019-02-22 | Synthon Biopharmaceuticals B.V. | Postupak pročišćavanja protutijela |
| BR112015014991B1 (pt) | 2013-01-17 | 2024-01-23 | Janssen Pharmaceuticals, Inc | Anticorpo específico para e. coli mdr, plasmídeo, cassete de expressão, célula hospedeira, método de produção do anticorpo, método para identificar um anticorpo candidato, preparação farmacêutica e de diagnóstico, epítopo, imunogênio e ácido nucleico utilizados |
| CA2910584A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| WO2015063693A1 (en) * | 2013-10-30 | 2015-05-07 | Hadasit Medical Research Services And Development Limited | Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis |
| CN106536551B (zh) | 2014-02-06 | 2021-04-16 | X4制药(奥地利)有限责任公司 | 大肠杆菌特异性抗体序列 |
| EA035991B9 (ru) | 2014-02-24 | 2020-10-21 | Глаксосмитклайн Байолоджикалс С.А. | Новый полисахарид и его применения |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| US20190134096A1 (en) * | 2016-05-06 | 2019-05-09 | Hadasit Medical Research Services & Development Limited | Hyperimmune colostrum in the modulation and treatment of conditions associated with the mammalian microbiome |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| WO2020010161A1 (en) * | 2018-07-02 | 2020-01-09 | Pure Tech Health Llc | Milk vesicles for use in delivering biological agents |
| CN112996808A (zh) * | 2018-10-03 | 2021-06-18 | 埃努贝尔拜欧公司 | 用于治疗动物急性腹泻和肠道感染的组合物和方法 |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| AU2019394947B2 (en) * | 2018-12-05 | 2025-09-11 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
| US12263192B2 (en) | 2019-02-26 | 2025-04-01 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
| MY205586A (en) | 2019-03-18 | 2024-10-28 | Janssen Pharmaceuticals Inc | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| WO2021168321A1 (en) * | 2020-02-19 | 2021-08-26 | Anubis Bio Corporation | Composition and methods for treating infectious agents using pathogen-specific antibodies |
| KR20230043157A (ko) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 다가 백신 조성물 및 이의 용도 |
| JP2024522404A (ja) * | 2021-04-16 | 2024-06-20 | プロディジー バイオテック | アルコール性肝疾患及び移植片対宿主病を治療又は予防するための高度免疫化卵製品 |
| US20250051426A1 (en) * | 2021-09-30 | 2025-02-13 | Igalphan corporation | Composition containing monoclonal antibody |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH627079A5 (en) | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
| US4550019A (en) | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
| JPS58154513A (ja) | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
| US4748018A (en) | 1984-02-07 | 1988-05-31 | Stolle Research & Development Corp. | Method of passive immunization of mammals using avian antibody |
| GB9105292D0 (en) * | 1991-03-13 | 1991-04-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
| EP0725789B1 (en) | 1993-09-20 | 2003-03-19 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
| DE4337654C2 (de) | 1993-11-04 | 1996-08-08 | Biotest Pharma Gmbh | Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat |
| JP2002516339A (ja) | 1998-05-27 | 2002-06-04 | ジェマ バイオテクノロジー リミテッド | ＬＡＩＴ／ｓＣＤ１４−蛋白質による抗生物質蛋白質およびペプチドの誘導 |
| DE19830607C2 (de) | 1998-07-09 | 2002-08-01 | Hte Ag The High Throughput Exp | Verfahren zum Nachweis eines Produktes im Abstrom eines katalytischen Materials einer Vielzahl von katalytischen Materialien |
| KR20040106298A (ko) | 2002-03-21 | 2004-12-17 | 아나디스 리미티드 | 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법 |
| IL165300A0 (en) | 2002-05-21 | 2005-12-18 | Anadis Ltd | Method of prophylaxis of infection |
| US9701737B2 (en) | 2003-02-19 | 2017-07-11 | Camas, Incorporated | Immunogen adherence and method of making and using same |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| US20070207187A1 (en) | 2004-09-29 | 2007-09-06 | Mizuo Yajima | Functional Composition Or Food Comprising Whey Protein, Antibody Derived From Milk Or Antibody |
| KR20070109985A (ko) | 2004-11-22 | 2007-11-15 | 아나디스 리미티드 | 생물활성 조성물 |
| US20100297140A1 (en) | 2006-08-31 | 2010-11-25 | A.C.N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust | Uses of antibodies |
| WO2009113065A1 (en) | 2008-03-13 | 2009-09-17 | Hadasit Medical Research Services & Development Ltd. | Immuno-modulating compositions for the treatment of immune-mediated disorders |
| AU2011290478B2 (en) | 2010-08-17 | 2014-11-13 | Hadasit Medical Research Services & Development Limited | Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
-
2010
- 2010-04-27 ES ES10721856.2T patent/ES2684696T3/es active Active
- 2010-04-27 CA CA3017477A patent/CA3017477A1/en not_active Abandoned
- 2010-04-27 AU AU2010243205A patent/AU2010243205B2/en active Active
- 2010-04-27 EA EA201171304A patent/EA024697B1/ru not_active IP Right Cessation
- 2010-04-27 WO PCT/IL2010/000339 patent/WO2010125565A2/en not_active Ceased
- 2010-04-27 EP EP18185733.5A patent/EP3461840A1/en not_active Withdrawn
- 2010-04-27 JP JP2012507877A patent/JP5740390B2/ja not_active Expired - Fee Related
- 2010-04-27 EP EP10721856.2A patent/EP2424890B1/en not_active Not-in-force
- 2010-04-27 DK DK10721856.2T patent/DK2424890T3/en active
- 2010-04-27 KR KR1020117027634A patent/KR101785120B1/ko not_active Expired - Fee Related
- 2010-04-27 US US13/265,252 patent/US10117930B2/en active Active
- 2010-04-27 BR BRPI1014774-8A patent/BRPI1014774A2/pt not_active Application Discontinuation
- 2010-04-27 SG SG2011073582A patent/SG175142A1/en unknown
- 2010-04-27 MX MX2011011376A patent/MX2011011376A/es unknown
- 2010-04-27 CA CA2760096A patent/CA2760096C/en not_active Expired - Fee Related
-
2011
- 2011-10-25 IL IL215924A patent/IL215924B/en active IP Right Grant
-
2018
- 2018-11-02 US US16/179,696 patent/US20190209681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525376A5 (enExample) | ||
| Wang et al. | Systematic review: chronic viral hepatitis and metabolic derangement | |
| EA201391262A1 (ru) | Композиция, способ лечения и диагностики стеатоза печени как самостоятельного заболевания или в комбинации с инфекцией гепатита с | |
| Sun et al. | Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection | |
| Cheng et al. | Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? | |
| SMT201500132B (it) | Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate | |
| JP2017515854A5 (enExample) | ||
| JP2016530279A5 (enExample) | ||
| JP2010520200A5 (enExample) | ||
| WO2015003122A3 (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| Arain et al. | A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients | |
| WO2011145885A3 (ko) | B형 간염 치료활성 물질의 스크리닝용 조성물 및 스크리닝 방법 | |
| JP2015209424A5 (enExample) | ||
| JP2012102100A5 (enExample) | ||
| HRP20211727T1 (hr) | Liječenja nealkoholnog steatohepatitisa (nash) | |
| 李佳美 | The activation of NLRP3 inflammasome involved in the decrease of BDNF induced by CUMS | |
| Wang et al. | NKT cells in liver fibrosis: Controversies or complexities | |
| 许刚 et al. | MiR-221 accentuates IFN's anti-HCV effect by downregulating SOCS1 and SOCS3 | |
| Wang et al. | THE EFFICACY OF INDIVIDUALIZED PEGINTERFERON ALFA-2A THERAPY AND ITS INFLUENCE ON HISTOLOGICAL RESPONSE IN THE MANAGEMENT OF HBEAG-POSITIVE CHB PATIENTS: 239 | |
| Feitelson | Putative mechanisms of hepatitis B and hepatitis C viruses in the pathogenesis of hepatocellular carcinoma (HCC) | |
| Sadhukhan et al. | Elevated Level of Liver Enzymes is not a Serum Marker for Hepatitis C Virus Infection among ß-Thalassemic Individuals | |
| Kozbial et al. | retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals. | |
| Cao et al. | INTERFERON/PEGINTERFERON PLUS NUCLEOS (T) IDE ANALOGS IN HBEAG-POSITIVE CHRONIC HEPATITIS B-VERY POTENT HBSAG RESPONSE: 240 | |
| Hotho | Chronic Hepatitis C Infection: Clinical and Societal Evaluations | |
| HAN et al. | Effect of Lamivudine Treatment in Renal Transplant Recipient with HBsAg-Positivity |